niacinamide has been researched along with Chronic Kidney Diseases in 17 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ischemia-reperfusion injury (IRI) is a model for AKI, which results in tubular damage, dysfunction of the mitochondria and autophagy, and in decreased cellular nicotinamide adenine dinucleotide (NAD+) with progressing fibrosis resulting in CKD." | 8.02 | Effect of NAD+ boosting on kidney ischemia-reperfusion injury. ( Andersen, CB; Egstrand, S; Lewin, E; Mace, ML; Morevati, M; Nordholm, A; Olgaard, K; Salmani, R, 2021) |
| " However, niacin can cause flushing and niacinamide probably cause thrombocytopenia." | 4.90 | Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2014) |
| " Ischemia-reperfusion injury (IRI) is a model for AKI, which results in tubular damage, dysfunction of the mitochondria and autophagy, and in decreased cellular nicotinamide adenine dinucleotide (NAD+) with progressing fibrosis resulting in CKD." | 4.02 | Effect of NAD+ boosting on kidney ischemia-reperfusion injury. ( Andersen, CB; Egstrand, S; Lewin, E; Mace, ML; Morevati, M; Nordholm, A; Olgaard, K; Salmani, R, 2021) |
| " Treatment discontinuation due to adverse events was 1." | 2.84 | Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. ( Brazier, M; Brisset, S; Choukroun, G; El Esper, N; Fournier, A; Kamel, S; Lemaire-Hurtel, AS; Lenglet, A; Liabeuf, S; Mansour, J; Mary, A; Massy, ZA; Mentaverri, R, 2017) |
| "Hyperphosphatemia is thought to be a central-risk factor for CKD-MBD." | 1.42 | Niacin and Chronic Kidney Disease. ( Masuda, M; Miyamoto, K; Segawa, H; Takeda, E; Taketani, Y; Tatsumi, S; Yamamoto, H; Yamanaka-Okumura, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 7 (41.18) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Rong, G | 1 |
| Gu, J | 1 |
| Fan, C | 1 |
| Guo, T | 1 |
| Jiang, T | 1 |
| Deng, W | 1 |
| Xie, J | 1 |
| Su, Z | 1 |
| Yu, Q | 1 |
| Mai, J | 1 |
| Zheng, R | 1 |
| Chen, X | 1 |
| Tang, X | 1 |
| Zhang, J | 1 |
| Takahashi, R | 1 |
| Kanda, T | 1 |
| Komatsu, M | 1 |
| Itoh, T | 1 |
| Minakuchi, H | 1 |
| Urai, H | 1 |
| Kuroita, T | 1 |
| Shigaki, S | 1 |
| Tsukamoto, T | 1 |
| Higuchi, N | 1 |
| Ikeda, M | 1 |
| Yamanaka, R | 1 |
| Yoshimura, N | 1 |
| Ono, T | 1 |
| Yukioka, H | 1 |
| Hasegawa, K | 1 |
| Tokuyama, H | 1 |
| Wakino, S | 1 |
| Itoh, H | 1 |
| Kalantari, S | 1 |
| Chashmniam, S | 1 |
| Nafar, M | 1 |
| Samavat, S | 1 |
| Rezaie, D | 1 |
| Dalili, N | 1 |
| Faivre, A | 1 |
| Katsyuba, E | 1 |
| Verissimo, T | 1 |
| Lindenmeyer, M | 1 |
| Rajaram, RD | 1 |
| Naesens, M | 1 |
| Heckenmeyer, C | 1 |
| Mottis, A | 1 |
| Feraille, E | 1 |
| Cippà, P | 1 |
| Cohen, C | 1 |
| Longchamp, A | 1 |
| Allagnat, F | 1 |
| Rutkowski, JM | 1 |
| Legouis, D | 1 |
| Auwerx, J | 1 |
| de Seigneux, S | 1 |
| Kumakura, S | 1 |
| Sato, E | 1 |
| Sekimoto, A | 1 |
| Hashizume, Y | 1 |
| Yamakage, S | 1 |
| Miyazaki, M | 1 |
| Ito, S | 1 |
| Harigae, H | 1 |
| Takahashi, N | 1 |
| Morevati, M | 1 |
| Egstrand, S | 1 |
| Nordholm, A | 1 |
| Mace, ML | 1 |
| Andersen, CB | 1 |
| Salmani, R | 1 |
| Olgaard, K | 1 |
| Lewin, E | 1 |
| Fouque, D | 1 |
| Vervloet, M | 1 |
| Ketteler, M | 1 |
| Kaesler, N | 1 |
| Goettsch, C | 1 |
| Weis, D | 1 |
| Schurgers, L | 1 |
| Hellmann, B | 1 |
| Floege, J | 1 |
| Kramann, R | 1 |
| Saurette, M | 1 |
| Alexander, RT | 1 |
| Lenglet, A | 3 |
| Fabresse, N | 1 |
| Taupin, M | 1 |
| Gomila, C | 1 |
| Liabeuf, S | 3 |
| Kamel, S | 3 |
| Alvarez, JC | 1 |
| Drueke, TB | 1 |
| Massy, ZA | 3 |
| Ix, JH | 2 |
| Isakova, T | 1 |
| Larive, B | 1 |
| Raphael, KL | 1 |
| Raj, DS | 1 |
| Cheung, AK | 1 |
| Sprague, SM | 1 |
| Fried, LF | 1 |
| Gassman, JJ | 1 |
| Middleton, JP | 1 |
| Flessner, MF | 1 |
| Block, GA | 1 |
| Wolf, M | 1 |
| Yeung, WG | 1 |
| Toussaint, ND | 1 |
| Badve, SV | 1 |
| He, YM | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Yang, ZH | 1 |
| Liao, YH | 1 |
| Taketani, Y | 1 |
| Masuda, M | 1 |
| Yamanaka-Okumura, H | 1 |
| Tatsumi, S | 1 |
| Segawa, H | 1 |
| Miyamoto, K | 1 |
| Takeda, E | 1 |
| Yamamoto, H | 1 |
| El Esper, N | 1 |
| Brisset, S | 1 |
| Mansour, J | 1 |
| Lemaire-Hurtel, AS | 2 |
| Mary, A | 2 |
| Brazier, M | 1 |
| Mentaverri, R | 1 |
| Choukroun, G | 1 |
| Fournier, A | 1 |
| Ginsberg, C | 1 |
| Bodeau, S | 1 |
| Louvet, L | 1 |
| Boullier, A | 1 |
| Jonet, A | 1 |
| Sonnet, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease (TOP-CKD)[NCT04258397] | Phase 2 | 200 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE[NCT02258074] | Phase 2 | 205 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline to 12 months in FGF23 level. (NCT02258074)
Timeframe: Baseline to 12 months
| Intervention | pg/ml (Mean) |
|---|---|
| Lanthanum Carbonate + Nicotinamide | .047 |
| Lanthanum Carbonate + Nicotinamide Placebo | -.003 |
| Lanthanum Carbonate Placebo and Nicotinamide | .193 |
| Lanthanum Carbonate Placebo and Nicotinamide Placebo | .138 |
Change from Baseline to 12 months in serum phosphate level (NCT02258074)
Timeframe: Baseline to 12 months
| Intervention | mg/dl (Mean) |
|---|---|
| Lanthanum Carbonate + Nicotinamide | 0.06 |
| Lanthanum Carbonate + Nicotinamide Placebo | 0.06 |
| Lanthanum Carbonate Placebo and Nicotinamide | 0.12 |
| Lanthanum Carbonate Placebo and Nicotinamide Placebo | 0.12 |
4 reviews available for niacinamide and Chronic Kidney Diseases
| Article | Year |
|---|---|
Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.
Topics: Animals; Carrier Proteins; Chelating Agents; Drug Therapy, Combination; Gastrointestinal Tract; Huma | 2018 |
Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.
Topics: Flushing; Humans; Lipoproteins, HDL; Niacin; Niacinamide; Phosphorus; Randomized Controlled Trials a | 2014 |
Nicotinamide and phosphate homeostasis in chronic kidney disease.
Topics: Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Homeostasis; Humans; Hyperphosphatemia; N | 2016 |
N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin.
Topics: Animals; Humans; Niacinamide; Renal Insufficiency, Chronic; Toxins, Biological; Uremia | 2016 |
3 trials available for niacinamide and Chronic Kidney Diseases
| Article | Year |
|---|---|
Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?
Topics: Aged; Endotoxemia; Endotoxins; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Human | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerul | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerul | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerul | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerul | 2019 |
Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.
Topics: Adult; Aged; Female; Humans; Hyperphosphatemia; Male; Middle Aged; Niacinamide; Phosphorus; Prospect | 2017 |
10 other studies available for niacinamide and Chronic Kidney Diseases
| Article | Year |
|---|---|
Nicotinamide N-methyltransferase ameliorates renal fibrosis by its metabolite 1-methylnicotinamide inhibiting the TGF-β1/Smad3 pathway.
Topics: Animals; Cells, Cultured; Fibrosis; Kidney; Male; Mice; Mice, Inbred C57BL; Niacinamide; Nicotinamid | 2022 |
The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease.
Topics: Animals; Female; Fibrosis; Humans; Male; Methionine; Mice; NAD; Niacinamide; Nicotinamide N-Methyltr | 2022 |
A Noninvasive Urine Metabolome Panel as Potential Biomarkers for Diagnosis of T Cell-Mediated Renal Transplant Rejection.
Topics: Acute Disease; Adenosine Diphosphate; Adult; Biomarkers; Cholesterol Esters; Cross-Sectional Studies | 2020 |
Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Disease Prog | 2021 |
Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease.
Topics: Adenine; Animals; Citric Acid Cycle; Disease Models, Animal; Disease Progression; Energy Metabolism; | 2021 |
Effect of NAD+ boosting on kidney ischemia-reperfusion injury.
Topics: Acute Kidney Injury; Animals; Autophagy; Disease Progression; Fibrosis; Glucuronidase; Kidney; Kloth | 2021 |
Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia.
Topics: Animals; Cells, Cultured; Humans; Magnesium; Male; Mice; Mice, Inbred DBA; Muscle, Smooth, Vascular; | 2020 |
Intestinal phosphate absorption: The paracellular pathway predominates?
Topics: Animals; Clinical Trials as Topic; Diet, Western; Electrochemistry; Enterocytes; Humans; Hyperphosph | 2019 |
Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.
Topics: Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Niacinamide; Phosphates; Renal Insu | 2019 |
Niacin and Chronic Kidney Disease.
Topics: Biological Transport; Bone Diseases; Cardiovascular Diseases; Dyslipidemias; Humans; Hyperphosphatem | 2015 |